Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Santen Pharmaceutical Co., Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned among 4 examiners and 4 art units, showing that the current docket spans distinct examination channels.
SOROUSH, LAYLA is the busiest examiner, with 1 pending action. Each assignment requires its own examiner-specific review, so a uniform prosecution approach may need adjustment for the separate art-unit contexts.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (75%) |
| Double-patenting only | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269474 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION CONTAINING EPI-NASTINE OR SALT THEREOF | STEVENS, MARK V | 28d |
| 18851269 | STERILIZATION METHOD OF PHARMACEUTICAL PREPARATION AND PACKAGING | SOROUSH, LAYLA | — |
| 18625513 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | RODRIGUEZ, RAYNA B | — |
| 18031516 | STABLE PHARMACEUTICAL COMPOSITION | HAVLIN, ROBERT H | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1628 | 1 |
| 1613 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18851269 | STERILIZATION METHOD OF PHARMACEUTICAL PREPARATION AND PACKAGING | SOROUSH, LAYLA | 1622 | §103 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18625513 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | RODRIGUEZ, RAYNA B | 1628 | DP | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18269474 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION CONTAINING EPI-NASTINE OR SALT THEREOF | STEVENS, MARK V | 1613 | §103 | Non-Final OA | 28d | Pending | Jun 23, 2023 |
| 18031516 | STABLE PHARMACEUTICAL COMPOSITION | HAVLIN, ROBERT H | 1626 | §103 | Final Rejection | — | Pending | Apr 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSanten Pharmaceutical Co., Ltd. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Layla Soroush has the most, with 1 of Santen Pharmaceutical Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
